The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir

被引:178
|
作者
Kempf, DJ
Rode, RA
Xu, Y
Sun, E
Heath-Chiozzi, ME
Valdes, J
Japour, AJ
Danner, S
Boucher, C
Molla, A
Leonard, JM
机构
[1] Abbott Labs, Antiviral Venture, Div Pharmaceut Prod, Abbott Pk, IL 60064 USA
[2] Abbott Labs, Dept Biostat, Abbott Pk, IL 60064 USA
[3] Abbott Labs, Dept Infect Dis Res, Abbott Pk, IL 60064 USA
[4] Univ Amsterdam, Acad Med Ctr, Div Infect Dis Trop Med & AIDS, NL-1105 AZ Amsterdam, Netherlands
[5] Univ Utrecht, Univ Hosp, Eijkman Winkler Inst Med & Clin MIcrobiol, Utrecht, Netherlands
关键词
viral load; durability of response; protease inhibitor; resistance;
D O I
10.1097/00002030-199805000-00001
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: To determine markers that are associated with the durability of virologic response to therapy with HIV protease inhibitors in HIV-infected individuals. Design: This study encompassed two retrospective analyses of the duration of virologic response to protease inhibitor therapy. The first analysis included 29 patients receiving either monotherapy or combination therapy with the protease inhibitor ritonavir whose plasma HIV RNA levels rebounded from the point of greatest decline with mutations associated with resistance to ritonavir. The second analysis included a cohort of 102 patients who initially responded to randomized treatment with either monotherapy with ritonavir or combination therapy with ritonavir and zidovudine. Methods: Durability of response was defined as the time from the initiation of therapy to the point at which plasma HIV RNA displayed a sustained increase of at least 0.6 log(10) copies/ml from the nadir value. In the first analysis, durability of response was analyzed with respect to baseline HIV RNA, HIV RNA at the nadir, and the drop in HIV RNA from baseline to the nadir. In the second analysis, time to rebound was examined using Kaplan-Meier analysis, stratifying by either baseline HIV RNA or HIV RNA at the nadir. Results: In both analyses, the durability of response was not highly associated with either baseline RNA or the magnitude of RNA decline from baseline. Instead, a strong relationship was observed between the durability of response and the nadir plasma HIV-1 RNA value (P < 0.01). The nadir in viral load was generally reached after 12 weeks of randomized therapy. Conclusions: Viral RNA determinations at intermediate timepoints may be prognostic of impending virologic failure of protease inhibitor therapy. Therapeutic strategies that allow intensification of initial antiretroviral regimens in the subset of patients with incomplete virological response before the emergence of high level resistance should be investigated. (C) 1998 Rapid Science Ltd.
引用
收藏
页码:F9 / F14
页数:6
相关论文
共 50 条
  • [1] Duration of viral suppression in patients on stable therapy for HIV-1 infection is predicted by plasma HIV RNA level after 1 month of treatment
    Maggiolo, F
    Migliorino, M
    Pirali, A
    Pravettoni, G
    Caprioli, S
    Suter, F
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2000, 25 (01) : 36 - 43
  • [2] Protease inhibitor resistance in HIV-1 infection
    Resch, W
    Swanstrom, R
    REVIEWS IN MEDICAL MICROBIOLOGY, 2000, 11 (04) : 211 - 221
  • [3] Effect of early antiretroviral therapy during primary HIV-1 infection on cell-associated HIV-1 DNA and plasma HIV-1 RNA
    Gianella, Sara
    von Wyl, Viktor
    Fischer, Marek
    Niederoest, Barbara
    Battegay, Manuel
    Bernasconi, Enos
    Cavassini, Matthias
    Rauch, Andri
    Hirschel, Bernard
    Vernazza, Pietro
    Weber, Rainer
    Joos, Beda
    Guenthard, Huldrych F.
    ANTIVIRAL THERAPY, 2011, 16 (04) : 535 - 545
  • [4] HIV-1 protease inhibitor
    Lloyd, AW
    DRUG DISCOVERY TODAY, 1996, 1 (06) : 261 - 261
  • [5] QUANTIFICATION OF HIV-1 RNA IN PLASMA USING NASBA (TM) DURING HIV-1 PRIMARY INFECTION
    VANGEMEN, B
    KIEVITS, T
    SCHUKKINK, R
    VANSTRIJP, D
    MALEK, LT
    SOOKNANAN, R
    HUISMAN, HG
    LENS, P
    JOURNAL OF VIROLOGICAL METHODS, 1993, 43 (02) : 177 - 188
  • [6] A PRELIMINARY-STUDY OF RITONAVIR, AN INHIBITOR OF HIV-1 PROTEASE, TO TREAT HIV-1 INFECTION
    MARKOWITZ, M
    SAAG, M
    POWDERLY, WG
    HURLEY, AM
    HSU, A
    VALDES, JM
    HENRY, D
    SATTLER, F
    LAMARCA, A
    LEONARD, JM
    HO, DD
    NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (23): : 1534 - 1539
  • [7] Duration of HIV-1 Viral Suppression on Cessation of Antiretroviral Therapy in Primary Infection Correlates with Time on Therapy
    Stoehr, Wolfgang
    Fidler, Sarah
    McClure, Myra
    Weber, Jonathan
    Cooper, David
    Ramjee, Gita
    Kaleebu, Pontiano
    Tambussi, Giuseppe
    Schechter, Mauro
    Babiker, Abdel
    Phillips, Rodney E.
    Porter, Kholoud
    Frater, John
    PLOS ONE, 2013, 8 (10):
  • [8] HIV-1 plasma RNA and risk of HIV-1 transmission
    Lingappa, J. R.
    Hughes, J. P.
    Donnel, D.
    Baeten, J. M.
    Mullins, J. I.
    Campbell, M. S.
    Gray, G. E.
    Essex, M.
    Farquhar, C.
    Rees, H.
    Wald, A.
    Corey, L.
    Celum, C.
    RETROVIROLOGY, 2009, 6
  • [9] High levels of cervical HIV-1 RNA during early HIV-1 infection
    Lavreys, Ludo
    Baeten, Jared M.
    Panteleeff, Dana D.
    Richardson, Barbra A.
    McClelland, R. Scott
    Chohan, Varsha
    Mandaliya, Kishorchandra
    Ndinya-Achola, Jeckoniah O.
    Overbaugh, Julie
    AIDS, 2006, 20 (18) : 2389 - 2390
  • [10] Inhibition of HIV-1 replication by a peptide dimerization inhibitor of HIV-1 protease
    Davis, David A.
    Brown, Cara A.
    Singer, Kathleen E.
    Wang, Victoria
    Kaufman, Joshua
    Stahl, Stephen J.
    Wingfield, Paul
    Maeda, Kenji
    Harada, Shigeyoshi
    Yoshimura, Kazuhisa
    Kosalaraksa, Pope
    Mitsuya, Hiroaki
    Yarchoan, Robert
    ANTIVIRAL RESEARCH, 2006, 72 (02) : 89 - 99